SIT­U­A­TION

• Head­quar­tered in Longview, Texas, Safe­script Phar­ma­cies, Inc. (“the Com­pa­ny”) sup­port­ed an under­served patient pop­u­la­tion uti­liz­ing a tech­nol­o­gy dri­ven bun­dled pre­scrip­tion solu­tion to aggre­gate select physi­cian spe­cial­ists and their pre­scrib­ing require­ments at the point-of-care
  
• Through a total of thir­teen (13) retail phar­ma­cies geo­graph­i­cal­ly dis­persed through­out the South­ern Unit­ed States, the Com­pa­ny serves patient pop­u­la­tions not effec­tive­ly ser­viced by most retail phar­ma­cies and empha­sizes spe­cial­ty med­ica­tions that require spe­cial han­dling or packaging
  
• In addi­tion, the Com­pa­ny pro­vides ancil­lary ser­vices relat­ed to eli­gi­bil­i­ty, ful­fill­ment, insur­ance verification/​authorization and payment
  
• The com­pa­ny vio­lat­ed fed­er­al reg­u­la­tions and Chap­ter 11 was required
  
• Chi­ron was engaged by the Com­pa­ny to advise in a sale of sub­stan­tial­ly all of its assets under Sec­tion 363 of the US Bank­rupt­cy Code
  

OUT­COME

• Chi­ron suc­cess­ful­ly nego­ti­at­ed with US Fed­er­al Reg­u­la­to­ry Depart­ment (FDA) regard­ing the sale of the assets of the Company
• Chi­ron suc­cess­ful­ly com­plet­ed the sale of the Com­pa­ny to SS Acqui­si­tion LLC

“Chi­ron suc­cess­ful­ly nego­ti­at­ed with US Food and Drug Admin­is­tra­tion to com­plete the sale of the assets of the com­pa­ny to SS Acqui­si­tion LLC.” — Safe­script Phar­ma­cies, Inc.